Co-Diagnostics (NASDAQ:CODX) perks up 10% premarket on light volume on the heels of performance data on its LogixSmart real-time PCR test that detects RNA from the SARS-CoV-2 virus in lower respiratory tract fluids.
Tests performed in Australia (n=207), India (n=45)
and Mexico (n not provided) showed 100% sensitivity and 100%
specificity with no cross-reactivity with other viruses.
It also says that the test detected more low-level
positives than the CDC assay while testing at the Minnesota Department
of Health showed 100% concordance with another (unnamed) assay.
https://seekingalpha.com/news/3567516-co-diagnostics-up-10-premarket-on-covidminus-19-test-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.